Lawrence Gimple headshot

Lawrence W. Gimple

Unit: School of Medicine
Department: Department of Medicine, Cardiovascular Medicine
Office location and address
Heart and Vascular Center
1215 Lee St
Charlottesville, Virginia 22903
Harvard Medical School, 1983, MD
Residency, Internal Medicine, Massachusetts General Hospital
Fellowship, Cardiology and Interventional Cardiology, Massachusetts General Hospital

Dr. Gimple was born in Nashville, Tennessee, but grew up near the beach in Wilmington, North Carolina. He was a Morehead Scholar at the University of North Carolina, Chapel Hill, and received his medical degree from Harvard Medical School. He completed all of his internal medicine and cardiology training at the Massachusetts General Hospital in Boston.

Dr. Gimple has been at UVA since 1989 and has been involved in the Cardiac Catheterization Laboratory since that time. He also has always been deeply involved with critical care cardiology in the Coronary Care Unit (CCU), and previously served as the CCU director. Dr. Gimple has an outpatient practice in cardiology and works in the myocardial infarction (MI) clinic. He is currently the director of clinical cardiology and the quality director for UVA Heart and Vascular Center, working to assure the best possible care across all UVA Health System services.

He loves being involved in the community and serves on a number of local boards, including the Piedmont Family YMCA. His interests include community programs that prevent diabetes, and he works with a community walking program. He has a special interest in “learn-to-swim,” which includes broadly supporting programs that assure that all the children in central Virginia have an opportunity to learn how to swim. Both of his sons were competitive swimmers in Virginia.

MD-INMD A Parallel Group Study to Determine the Efficacy and Safety the REG1 Anticoagulatoin System Compared to Bivallrudin in Subjects Undergoing Percutaneous Coronary Intervention (REGULATE-PCI)
Source: Regado Biosciences, Inc.
November 04, 2013 – October 31, 2023
Source: LabCorp Drug Development, Inc.
May 30, 2013 – October 01, 2022
CareTaker Self-Calibration Validation
Source: CareTaker Medical LLC
July 18, 2018 – July 17, 2021
MD-INMD-CV Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study (ARTEMIS)
Source: Duke University
November 05, 2015 – November 05, 2018
Ticagrelor Trial for AstraZeneca and Brigham and Women's Hospital
Source: Brigham & Women's Hospital, Inc.
April 19, 2011 – June 30, 2016
Medtronic Protect Continued Access Post Marketing Surveillance Trial
Source: Medtronic Vascular, Inc.
February 25, 2009 – February 23, 2016
MD-INMD-CV An economic study to estimate the cost of Intra-procedural thrombotic events in a dataset of percutaneous coronary intervention patients receiving cangrelor or clopidogrel (PHOENIX ECONOMICS)
Source: The Medicines Company
September 13, 2013 – May 31, 2015
MD-INMD NCIIA E-team Program
Source: The National Collegiate Inventors & Innovators All
July 01, 2013 – January 31, 2015
Daloutcomes 2
Source: Genentech, Inc
March 13, 2012 – February 28, 2014
Source: The Medicines Company
October 22, 2010 – October 21, 2013
MD-INMD Dalcetrapib on CV Risk in Stable CHD Patients with Recent ACS
Source: Hoffman La Roche
October 28, 2009 – May 31, 2013
MD-INMD CV252 Trilogy ACS Study-Comparison of Prasugrel and Clopidogrel in ACS Subjects with USA/NSTEMI who are Medically Managed
Source: IQVIA RDS Inc.
September 25, 2008 – March 31, 2013